Stockscreener 앱 받기
37.50
0.73%
0.27
전일 마감가:
$37.23
열려 있는:
$37.35
하루 거래량:
1.06M
Relative Volume:
0.80
시가총액:
$2.79B
수익:
-
순이익/손실:
$-275.16M
주가수익비율:
-9.6401
EPS:
-3.89
순현금흐름:
$-221.15M
1주 성능:
+3.71%
1개월 성능:
+3.79%
6개월 성능:
+4.43%
1년 성능:
-15.02%
1일 변동 폭
$36.85
$39.10
1주일 범위
$35.36
$39.10
52주 변동 폭
$28.21
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
명칭
Springworks Therapeutics Inc
전화
203-883-9490
주소
100 WASHINGTON BOULEVARD, STAMFORD, CT
SWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
37.50 | 2.79B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-20 | 개시 | Evercore ISI | Outperform |
| 2024-02-05 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-03-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-04 | 개시 | H.C. Wainwright | Buy |
| 2019-10-08 | 개시 | Cowen | Outperform |
| 2019-10-08 | 개시 | Goldman | Buy |
| 2019-10-08 | 개시 | JP Morgan | Overweight |
| 2019-10-08 | 개시 | Wedbush | Outperform |
모두보기
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
Vanguard Group Inc. Expands Holdings in SpringWorks Therapeutics Inc. - GuruFocus.com
SpringWorks Therapeutics to Report Fourth Quarter and Full - GlobeNewswire
SpringWorks Therapeutics Plans Major Q4 Update: Key Business Milestones & 2024 Performance Review - StockTitan
Learn to Evaluate (SWTX) using the Charts - Stock Traders Daily
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $70.00 Average PT from Analysts - Defense World
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 4.8%Here's What Happened - MarketBeat
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma - Marketscreener.com
AMI Asset Management Corp Takes $1.44 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.00 - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6.4%Time to Sell? - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 4.3%Time to Buy? - MarketBeat
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
SpringWorks Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - MSN
Research Analysts Set Expectations for SWTX FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for SWTX FY2027 Earnings - Defense World
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownHere's What Happened - MarketBeat
Wedbush Research Analysts Reduce Earnings Estimates for SWTX - MarketBeat
JPMorgan Chase & Co. Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics’ SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Items Tagged with 'RPT-04402' - BioWorld Online
Items Tagged with 'SW-3431' - BioWorld Online
Springworks licenses molecular glue targeting PP2A from Rappta - BioWorld Online
Why Springworks Therapeutics Stock is Tumbling - TipRanks
SpringWorks Therapeutics (NASDAQ:SWTX) Given Outperform Rating at Wedbush - Defense World
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
Wedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks to Develop Rappta’s First-in-Class Cancer Drug - Contract Pharma
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
SpringWorks Therapeutics Reports Strong 2024 Financial Results - TipRanks
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
SpringWorks Therapeutics Reports Preliminary Fourth Quarter - GlobeNewswire
SpringWorks Therapeutics Hits $172M Revenue in 2024 as OGSIVEO Launch Accelerates Growth - StockTitan
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate (SWTX) - Seeking Alpha
SpringWorks Therapeutics jumps amid takeover speculation - MSN
Guggenheim Lowers SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - Defense World
SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim - Yahoo Finance
Guggenheim Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - MarketBeat
Springworks Therapeutics Inc (SWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):